id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-2617-0007,FDA,FDA-2018-E-2617,Letter to Wilmer Cutler Pickering Hale and Dorr LLP  from United States Patent and Trademark Office,Other,Letter(s),2021-07-26T04:00:00Z,2021,7,2021-07-26T04:00:00Z,,2021-07-26T18:17:49Z,,0,0,0900006484c1019e
FDA-2018-E-2617-0006,FDA,FDA-2018-E-2617,Patent Term Extension Application Response Letter from FDA CDER to The Honorable Andrei Iancu,Other,Letter(s),2020-07-28T04:00:00Z,2020,7,2020-07-28T04:00:00Z,,2020-07-28T16:22:45Z,,0,0,09000064847ab791
FDA-2018-E-2617-0005,FDA,FDA-2018-E-2617,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-06-22T04:00:00Z,2020,6,2020-06-22T04:00:00Z,,2020-06-22T17:17:25Z,,0,0,09000064846feed7
FDA-2018-E-2617-0004,FDA,FDA-2018-E-2617,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,,2019-12-12T17:33:46Z,,0,0,0900006484208552
FDA-2018-E-2617-0003,FDA,FDA-2018-E-2617,"Determination of Regulatory Review Period for Purposes of Patent
Extension; VABOMERE",Notice,Determinations,2019-12-11T05:00:00Z,2019,12,2019-12-11T05:00:00Z,2020-02-11T04:59:59Z,2019-12-12T14:42:41Z,2019-26655,0,0,0900006484200d32
FDA-2018-E-2617-0002,FDA,FDA-2018-E-2617,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-07-24T04:00:00Z,2019,7,2019-07-24T04:00:00Z,,2019-07-24T14:50:26Z,,0,0,0900006483db162e
FDA-2018-E-2617-0001,FDA,FDA-2018-E-2617,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-09-18T04:00:00Z,2018,9,2018-09-18T04:00:00Z,,2018-09-18T18:25:57Z,,0,0,0900006483716759